Description
SGN-70 is a humanized anti-CD70 monoclonal antibody. CD70 is expressed on activated T- and B-cells but not resting lymphocytes, and has been associated with a variety of autoimmune and inflammatory disorders.

Status
Seattle Genetics is developing SGN-70 as a novel therapy for autoimmune disease. By specifically targeting activated T- and B-cells, SGN-70 may reduce the damaging effects of autoimmune disease without globally suppressing the immune system. We completed a phase I dose-escalation trial of SGN-70 to assess safety, tolerability and pharmacokinetics in healthy volunteers. A phase I trial is ongoing in patients with autoimmune disease.